Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed prostate cancer * Disease progression after prior castration * At least 3 rising PSA levels at least 1 week apart OR 2 rising levels at least 4 weeks apart * New osseous lesions on bone scan and/or more than 25% increase in bidimensionally measurable soft tissue disease or appearance of new sites of disease by CT scan or MRI * Testosterone no greater than 50 ng/mL * Medical therapy (e.g., gonadotropin-releasing hormone analogues) to maintain castrate level of testosterone should continue in the absence of surgical orchiectomy * Progression of disease after discontinuation of prior anti-androgen therapy * No requirement for palliative therapy within the past 12 weeks * No active CNS or epidural primary tumor OR active CNS or epidural metastases PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Karnofsky 60-100% Life expectancy: * Not specified Hematopoietic: * WBC greater than 3,500/mm3 * Platelet count greater than 100,000/mm3 Hepatic: * Bilirubin less than 1.5 mg/dL * Gamma-glutamyl-transferase less than upper limit of normal (ULN) * AST less than ULN * PT less than 14 seconds * No prior autoimmune hepatitis Renal: * Creatinine less than 1.5 mg/dL OR * Creatinine clearance greater than 60 mL/min Cardiovascular: * No clinically significant cardiac disease (New York Heart Association class III or IV) Pulmonary: * No severe debilitating pulmonary disease Other: * Fertile patients must use effective contraception * No active uncontrolled infection or infection requiring IV antibiotics * No prior autoimmune disease PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior murine protein for diagnostic or therapeutic purposes * No other concurrent anticancer immunotherapy Chemotherapy: * At least 4 weeks since prior chemotherapy and recovered * No concurrent anticancer chemotherapy Endocrine therapy: * See Disease Characteristics * No concurrent anticancer hormonal therapy Radiotherapy: * At least 4 weeks since prior radiotherapy and recovered * Concurrent radiotherapy to localized sites of disease (e.g., bone) allowed if the site does not contain sole measurable lesion Surgery: * See Disease Characteristics * No concurrent surgery Other: * Recovered from all prior therapy * At least 4 weeks since prior therapeutic investigational anticancer drugs * At least 4 weeks since prior participation in therapeutic clinical trial with an experimental drug * No prior diagnostic ProstaScint, Myoscint, or Oncoscint scans * No other concurrent therapeutic investigational anticancer agents * No concurrent participation in other therapeutic clinical trial with an experimental drug